Latest Breaking News On - Davidp luci - Page 2 : comparemela.com

Acurx Pharmaceuticals (ACXP) Granted FDA End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection

Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development

As previously announced, planning is underway with FDA to advance ibezapolstat into international Phase 3 clinical trials for treatment of C. difficile Infection As anticipated, an End of Phase 2.

Acurx Pharmaceuticals (ACXP) Announces Positive Extended Clinical Cure Data for Ibezapolstat

Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024, February 1, 2024

STATEN ISLAND - Acurx Pharmaceuticals, Inc. , a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced.

Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024

STATEN ISLAND, N.Y., Jan. 23, 2024 /PRNewswire/  Acurx Pharmaceuticals, Inc. , a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat.